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Abstract
Nearly 200 million people are infected by hepatitis C virus (HCV) worldwide. For replicating the HCV genome, the
membrane-associated machinery needs to be formed by both HCV non-structural proteins (including NS5B) and human
host factors such as VAPB. Recently, the 99-residue VAPC, a splicing variant of VAPB, was demonstrated to inhibit HCV
replication via binding to NS5B, thus acting as an endogenous inhibitor of HCV infection. So far, the structure of VAPC
remains unknown, and its interaction with NS5B has not been biophysically characterized. In this study, we conducted
extensive CD and NMR investigations on VAPC which led to several striking findings: 1) although the N-terminal 70 residues
are identical in VAPC and VAPB, they constitute the characteristic b-barrel MSP fold in VAPB, while VAPC is entirely
unstructured in solution, only with helical-like conformations weakly populated. 2) VAPC is indeed capable of binding to
NS5B, with an average dissociation constant (Kd) of ,20 mM. Intriguingly, VAPC remains dynamic even in the complex,
suggesting that the VAPC-NS5B is a ‘‘fuzzy complex’’. 3) NMR mapping revealed that the major binding region for NS5B is
located over the C-terminal half of VAPC, which is composed of three discrete clusters, of which only the first contains the
region identical in VAPC and VAPB. The second region containing ,12 residues appears to play a key role in binding since
mutation of 4 residues within this region leads to almost complete loss of the binding activity. 4) A 14-residue mimetic,
VAPC-14 containing the second region, only has a ,3-fold reduction of the affinity. Our study not only provides critical
insights into how a human factor mediates the formation of the HCV replication machinery, but also leads to design of
VAPC-14 which may be further used to explore the function of VAPC and to develop anti-HCV molecules.
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Introduction
Hepatitis C virus (HCV), first discovered in 1989, infects about
200 million people worldwide [1–3], and is a leading risk factor for
the development of severe chronic liver diseases including cirrhosis
and hepatocellular carcinoma [4]. HCV is a member of the
Flaviviridae family of enveloped, positive-stranded RNA viruses,
and has a genome of approximately 9.6 kb encoding a single
polyprotein of ,3,000 amino acids, which is subsequently
processed into 10 individual proteins by viral and cellular
proteases [5–9]. Interestingly, replication of positive-stranded
RNA viruses involves intracellular membrane structures, such as
the endoplasmic reticulum (ER), Golgi apparatus, endosome, and
lysosome [10]. The membrane-associated machinery copies the
RNA genome into a negative-strand intermediate, which is then
used to generate additional positive-stranded RNAs for subsequent
rounds of translation and packaging into virus particles. HCV
replication is initiated immediately after translation and processing
of the viral protein, and all HCV gene products remain associated
with intracellular membranes [11–17]. Although the exact
mechanisms, identities of the host factors and detailed interactions
among them are poorly understood, HCV nonstructural proteins
including NS3, NS4A, NS4B, NS5A, and NS5B have been
characterized to be the key components of the replication
machinery.
Thus far, no efficient HCV vaccine is available, and the most
common therapy is based on a combination of interferon-alpha
and ribavirin. However, this treatment has a success rate of only
,50%, with severe side effects [18,19]. As a consequence,
identification of novel targets to design HCV antiviral drugs is
urgently required [20–23]. At present, the most common targets
are two viral enzymes, i.e. the NS3/4A serine protease and the
NS5B RNA-dependent RNA polymerase [24], as they are
amenable to the development of biochemical assays for inhibitor
screening [25]. However, targeting enzymatic actions also appear
to have a considerable disadvantage, i.e. rapid development of
drug resistance [25,26]. Therefore, there is promising potential to
target non-enzymatic processes such as those required for RNA
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replication. Although how cyclophilins regulate HCV replication
remains unknown, a molecular chaperone cyclophilin A that
catalyzes the cis-trans isomerization of proline residues, has been
demonstrated to be an important drug target for chronic hepatitis
C therapy [27,28].
Recently, the formation of the HCV replication machinery has
been shown to require interactions of viral NS5A/NS5B to host
proteins including human vesicle-associated membrane protein-
associated protein (VAP) subtypes A and B [15–17]. NS5A is a
critical component of HCV replication [29], and is additionally
involved in the modulation of cell signaling pathways, interferon
response, pathogenesis, and apoptosis regulation [30]. Although
NS5B functions as an RNA-dependent RNA polymerase, it
appears also to engage in protein-protein interactions critical for
forming the replication machinery. Indeed, VAPC, a splicing
variant of VAPA/VAPB, was recently identified to block the HCV
RNA replication as well as HCV propagation. In particular,
VAPC expression has been detected in various tissues, but
Figure 1. Comparison of VAPC and VAPB-MSP. (a) Sequence alignment of the human 99-residue VAPC and 125-residue VAPB-MSP domain. The
first 70 residues (in red) are completely identical, while the rest (in blue) are different in the two proteins. The green arrow is used to separate the first
70 residues from the rest. (b, c) Crystal structure of the 125-residue VAPB-MSP domain that we previously determined (46), in which the 70 identical
residues are in red, while the different ones are in blue. (d) Secondary-structure prediction of VAPC by computational programs GOR4, Predator, and
SIMPA96. Red E, b-strand; blue H, helix; green C, random coil.
doi:10.1371/journal.pone.0040341.g001
Figure 2. Solution conformation of VAPC. (a) Far-UV CD spectra of VAPC at different pH values, i.e. 6.5 (green); 5.5 (purple); 4.5 (grey); 3.5 (cyan);
3.0 (red). (b) 1H-15N NMR HSQC spectrum of VAPC. The HSQC peaks for two Trp side chains are indicated by the red arrow. (c) Residue-specific 13Ca
conformational shift of VAPC derived from analysis of triple-resonance heteronuclear NMR spectra, including HNCACB and CBCA(CO)NH. Red arrows
are used to indicate two regions with undetectable HSQC peaks. Blue bars indicate residues different in VAPC and VAPB-MSP domain. Residues
located in the identical regions are in red if adopting b-strands; in green if adopting turn/loop conformations; in light brown if adopting helical
conformation, and in grey if highly unstructured.
doi:10.1371/journal.pone.0040341.g002
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negligibly in the liver. As a consequence, VAPC has been
proposed to be an endogenous inhibitor of HCV infection [31,32].
The human VAP family proteins were initially identified as
homologs of vesicle-associated membrane protein (VAMP)-associ-
ated protein (VAP) with a size of 33 kDa in Aplysia californica,
including VAPA, VAPB, VAPC, and several newly-identified
spliced variants [33–35]. VAPA and VAPB share ,60% sequence
identity, and are composed of three conserved domains, i.e. an N-
terminal immunoglobulin-like b sheet domain that has 22%
sequence identity to the major sperm protein (MSP); a central
coiled-coil domain; and a C-terminal transmembrane domain
[36–38]. On the other hand, the 99-residue VAPC lacking the
transmembrane segment possesses the N-terminal 70 residues
completely identical to the 125-residue MSP domain of VAPB,
and the C-terminal 29 residues unique in VAPC (Figure 1). VAP
proteins are ubiquitously expressed type II integral membrane
proteins that localize to the ER and pre-Golgi intermediates [39].
Moreover, VAP proteins target lipid-binding proteins carrying a
short motif containing two phenylalanines in an acidic tract (FFAT
motif) to the ER [36]. The FFAT-motif consists of the consensus
amino acid sequence EFFDAxE, which is conserved in several
lipid-binding protein families implicated in the transfer of lipids
between the ER and other organelles, such as the Golgi,
endosomes, and plasma membrane [40]. The VAP proteins also
interact with intracellular proteins (including Nir1, Nir2, and Nir3)
via the FFAT motif which differentially affects the organization of
the ER [41]. Recently, it was also shown that the VAPB-MSP
domain also serves as a ligand for Eph receptors [37,38,42].
Strikingly, two point mutations (P56S and T46I) in the VAPB
MSP domain have been identified to lead to familial amyotrophic
lateral sclerosis (ALS) with rapid progression or late-onset spinal
muscular atrophy [43,44].
Thus far, there is no structural and binding characterization of
VAPC and its interaction with NS5B. Such knowledge is essential
for the development of novel strategies to design inhibitory
molecules against HCV infection by targeting the VAPC-NS5B
interface [45]. Here, we first conducted an extensive structural
characterization of the full-length VAPC by CD and NMR
spectroscopy. Surprisingly, VAPC was characterized to be highly
disordered in solution, only with helical-like conformations weakly
populated over several segments. However, as unraveled by NMR
HSQC titrations that can provide residue-specific information
even for very weak bindings, VAPC was indeed capable of binding
to NS5B with three discrete regions, with an average dissociation
constant (Kd) of ,20 mM. Moreover, we mapped out critical
residues for binding, and subsequently obtained a 14-residue
mimetic designated as VAPC-14 which only exhibited a 3-fold
reduction of binding affinity to NS5B.
Results
VAPC is Highly-unstructured
The recombinant VAPC protein was overexpressed as a His-
tagged fusion protein in E. coli, and subsequently purified by Ni2+-
affinity chromatography under native conditions. Subsequently,
VAPC was separated from the His-tag by on-gel cleavage with
thrombin, and was further purified by HPLC on a reverse-phase
(RP) C8 column. As shown in Figure 2a, VAPC has far-UV CD
spectra typical of a highly-disordered protein with pH ranging
from 6.5 to 3, with the maximal negative signal at ,198 nm, and
lacking any positive signal at ,192 nm. However, there was a
small negative signal at ,225 nm, implying that the helical
conformation may be populated in VAPC to some degree. The
1H-15N NMR HSQC spectrum (Figure 2b) also indicated that
VAPC lacks any tight tertiary packing as evident from its very
narrow 1H (,0.9 ppm) and 15N (,19 ppm) spectral dispersions.
Consequently, it can be concluded that VAPC is predominantly
disordered, lacking of well-formed secondary structures and tight
tertiary packing.
By analyzing triple-resonance heteronuclear NMR spectra
including HNCACB and CBCA(CO)NH acquired on a
15N2/13C-labeled VAPC sample at a protein concentration of
300 mM, we succeeded in achieving its sequential assignment and
obtaining Ca conformational shifts of all residues except for
several in the C-terminal portion whose HSQC peaks were not
detected (Figure 2c). It is well-established that Ca chemical shift
deviations from their corresponding random-coil values are very
sensitive indicators of protein secondary structures, thus repre-
senting a powerful probe for detecting residual secondary
structures in unfolded or partially folded proteins [46,47]. As
judged from small but positive Ca conformational shifts over the
majority of VAPC residues (Figure 2c), it appeared that loop/
helical-like conformations were weakly populated over several
segments of the sequence, even over the first 70 residues which are
identical to the VAPB-MSP domain, and adopted b-sheet
secondary structures as demonstrated by our previous crystallo-
graphic and NMR characterization [37]. More precisely, over the
identical 70 residues, some residues adopting b-strands in the
VAPB-MSP transformed into loop or helical-like conformations in
VAPC (Figure 2c).
VAPC Forms a ‘‘Fuzzy Complex’’ with NS5B
Recently, it was discovered that by interacting with HCV
NS5B, the human VAPC acts as an inhibitor of HCV replication.
Therefore, in the present study, we cloned and expressed the HCV
NS5B protein. As shown in Figure 3a, NS5B has a far-UV CD
spectrum characteristic of a well-folded helix-dominant protein,
with two negative signals at ,209 and 222 nm, as well as a very
large positive signal at ,193 nm. However, due to the short
transverse relaxation time (T2) resulting from its very large
molecular size, the NMR resonance peaks are very broad
(Figure 3b). Nevertheless, the manifestation of several highly up-
field signals clearly demonstrate that NS5B is well-folded, with a
tight tertiary packing in solution.
Subsequently, we titrated the 15N-labeled VAPC protein with
the unlabeled NS5B. As shown in Figure 3c, addition of NS5B
triggered the shifts of many HSQC peaks of VAPC, indicating that
VAPC was indeed able to bind to NS5B. It is also noteworthy that
the HSQC spectral dispersions of VAPC did not significantly
increase even upon binding to NS5B, implying that VAPC
remained largely flexible even in the complex. On the other hand,
based on the sequential assignment, we were able to map the
perturbation of the HSQC peaks to the VAPC sequence
(Figure 3d). Interestingly, the most significantly-perturbed residues
are located on the C-terminal half of the VAPC sequence, mostly
composed of the residues unique to VAPC (Figure 3d).
Figure 3. Binding between VAPC and NS5B. (a) Far-UV CD spectrum of HCV NS5B. (b) One-dimensional 1H NMR spectrum of HCV NS5B. Blue
arrows are used to indicate very up-field NMR resonance peaks characteristic of a well-folded protein with tight tertiary packing. (c) Superimposition
of 1H-15N NMR HSQC spectra of VAPC in the absence of (blue) and in the presence of unlabeled NS5B (red) at a molar ratio of 1:1.5 (VAPC:NS5B). (d)
Residue-specific changes of integrated 1H and 15N chemical shifts of VAPC in the presence of unlabeled NS5B at a molar ratio of 1:1.5 (VAPC:NS5B).
doi:10.1371/journal.pone.0040341.g003
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Conformational and Binding Properties of VAPC-43
As most significantly-perturbed residues triggered by adding
NS5B are located on the C-terminal half of VAPC (Figure 3d), we
then cloned into a GST-fused expression vector a truncated
VAPC designated as VAPC-43 spanning residues 57–99
(Figure 4a). The recombinant VAPC-43 protein was over-
expressed in E. coli, and subsequently purified by affinity
chromatography with glutathione-Sepharose 4B beads. VAPC-
43 was released from the GST-fusion protein by on-gel cleavage
with thrombin, and was further purified by HPLC on a reverse-
phase (RP) C18 column.
As shown in Figure 4b, the 43-residue VAPC-43 is also highly
disordered in solution as evident from its far-UV CD spectra.
Furthermore, the lack of tight tertiary packing in VAPC-43 is
clearly evident from its narrow HSQC spectral dispersions
(Figure 4c). To gain residue-specific insights into the solution
conformation of VAPC-43, we collected a pair of three-
dimensional heteronuclear NMR spectra, namely 15N-edited
HSQC-TOCSY and HSQC-NOESY, and subsequently achieved
its sequential assignment. As judged from the negative Ha
conformational shifts for most residues (Figure 4d), VAPC-43
appears to have loop or helical-like conformations weakly-
populated over four segments, i.e. the first centered at Ile61-
Asp62; second at Asp77-Glu78, third at Pro86, and fourth at
Glu95-Gly96, similar to the patterns observed for Ca conforma-
tional shifts in the context of the full-length VAPC (Figure 3d).
Interestingly, the first helical segment is composed of residues
identical in both VAPC and VAPB-MSP domain. The existence of
the loop or helical-like segments was further supported by
characteristic NOEs (Figure 4e) over the VAPC-43 sequence
defining the helical conformation, including dNN(i, i+1), dNN(i, i+2),
daN(i, i+2), and daN(i, i+3). The existence of the loop or/and helical
conformations over the VAPC-unique region is consistent with the
prediction results of secondary structures (Figure 1d). However,
since no daN(i, i+4) NOEs were observed, the helical conformation
in VAPC-43 appears to be mainly dynamic 310-helix/loop, rather
than a-helix, consistent with the above CD result [56,57].
Although it is highly unstructured in solution, it is able to bind
NS5B as demonstrated by HSQC titrations of 15N-labeled VAPC-
43 with unlabeled NS5B (Figure 5a). However, even at a molar
Figure 4. Solution conformation of VAPC-43. (a) Amino acid sequence of VAPC showing the sequences of truncated VAPC-43 (over residues
57–99) and VAPC-14 (72–85). Green arrows indicate four residues which were mutated into Ala in a VAPC-43 construct. (b) Far-UV CD spectrum of
VAPC-43. (c) 1H-15N NMR HSQC spectrum of VAPC-43 with sequential assignments labeled. (d) Residue-specific Ha conformational shift of VAPC-43
derived from analysis of three-dimensional 15N-edited HSQC-TOCSY spectrum. Blue bars indicate residues identical to those in VAPB-MSP domain,
while red ones depict VAPC-specific residues. (e) Characteristic NOE connectivities of VAPC-43 defining secondary structures derived from analysis of
three-dimensional 15N-edited HSQC-NOESY spectrum.
doi:10.1371/journal.pone.0040341.g004
Figure 5. Binding of VAPC-43 with NS5B. (a) Superimposition of 1H-15N NMR HSQC spectra of VAPC-43 in the absence of (blue) and in the
presence of unlabeled NS5B at molar ratios of 1:1 (green) and 1:2.75 (red) (VAPC-43:NS5B). The shift tracings of Arg73 and Trp74 are zoomed in, and
shown as an inset. (b) Residue-specific changes of integrated 1H and 15N chemical shifts of VAPC-43 in the presence of unlabeled NS5B at molar ratios
of 1:0.5 (blue), 1:1 (green), and 1:2.75 (red) (VAPC-43:NS5B). (c, d) Experimental (dots) and fitted (lines) values are shown for VAPC-43 residues with
significant changes of the integrated 1H and 15N chemical shifts.
doi:10.1371/journal.pone.0040341.g005
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ratio of 1:2.5 (VAPC-43:NS5B) where the peak shifting of many
residues were largely saturated (Figure 5b), the HSQC spectral
dispersions still remained largely unchanged. This implies that like
the full-length VAPC, VAPC-43 also remains largely flexible
without any tight tertiary packing in the complex with NS5B. On
the other hand, as judged from the chemical shift differences
(Figure 5b), three discrete regions appears to be critical for binding
with NS5B, i.e. the first one centered at Ile62, second over Arg73-
Ala82, and third centered at Glu95. The first and third regions
contain only ,2 residues while the second spans ,10 residues.
To explore the role of the second region in binding to NS5B, we
thus mutated four residues (Arg73, Trp74, Glu78 and Asp80) into
Ala. We successfully expressed and purified the recombinant
mutant protein. The VAPC-43 mutant again appears to be highly
unstructured without any well-formed secondary structures as
judged from its far-UV spectrum (Figure 6a), and lacks any tight
tertiary packing as demonstrated by the very narrow HSQC
spectral dispersions (Figure 6b). On the other hand, the VAPC-43
mutant appears to undergo some dynamic aggregation, or/and
conformational exchanges on ms to ms time-scale, and conse-
quently the intensities of its HSQC peaks were not uniform, i.e.
some were very strong but some very weak (Figure 6b). We also
titrated 15N-labeled VAPC-43 mutant with unlabeled NS5B.
Remarkably, even at a molar ratio of 1:2.5 (VAPC-43
mutant:NS5B), no significant shift of the HSQC peaks was
observed (Figure 6b), clearing demonstrating that this second
region is indeed critical for binding with NS5B.
Conformational and Binding Properties of VAPC-14
Subsequently we cloned, expressed and purified a 14-residue
fragment designated as VAPC-14 containing residues Arg72-
Gln85. As shown in Figure 7a, VAPC-14 is highly disordered in
solution as evident from its far-UV CD spectra. Furthermore, the
lack of any tight tertiary packing is also evident from its narrow
HSQC spectral dispersions (Figure 7b). Nevertheless, VAPC-14
was able to bind NS5B as demonstrated by HSQC titrations of
15N-labeled VAPC-14 with unlabeled NS5B (Figures 7b, 7c).
Again, even at a molar ratio of 1:2.5 (VAPC-14:NS5B), the HSQC
spectral dispersions still remained largely unchanged (Figure 7b).
This indicates that like the full-length VAPC and VAPC-43, even
in the complex with NS5B, VAPC-14 remains largely flexible
without any tight tertiary packing.
We attempted to perform the ITC measurements on the
binding of NS5B to VAPC and its fragments, but failed to obtain
high-quality data, probably due to the complex binding mode,
and/or the fact that many VAPC residues still remain largely
flexible even in the complex. Therefore, to quantitatively assess the
binding between VAPC-43/VAPC-14 and NS5B, we fitted the
shift tracings of the VAPC-43/VAPC-14 HSQC peaks to obtain
dissociation constants (Kd) as we have previously conducted on
other systems [48,49]. The fitting is exemplified in Figures 5c and
d for VAPC-43 and 7d for VAPC-14, and the derived Kd values
are summarized in Table 1. Strikingly, the Kd value of VAPC-14
is 49.13 mM, only ,3-fold larger than that for VAPC-43
(18.29 mM), suggesting that deletion of the first and third binding
regions only resulted in a 3-fold reduction of the binding affinity to
NS5B.
Discussion
The human VAPC is a 99-residue splicing variant of the 243-
residue VAPB, with the N-terminal 70 residues being identical in
Figure 6. Binding of VAPC-43 mutant with NS5B. (a) Far-UV CD spectrum of VAPC-43 mutant. (b) Superimposition of 1H-15N NMR HSQC spectra
of VAPC-43 mutant in the absence of (blue) and in the presence of unlabeled NS5B at a molar ratio of 1:2.0 (red) (VAPC-43 mutant:NS5B).
doi:10.1371/journal.pone.0040341.g006
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both proteins. As demonstrated in the crystal structure of the
human VAPB-MSP domain that we previously determined [37],
the 70 residues adopt b-strand or turn secondary structures
(Figure 1). Prediction of the VAPC secondary structures by several
computational programs, including GOR4 [50], Predator [51],
and SHIMPA96 [52], also suggest that several fragments within
the identical 70 residues possess high intrinsic propensity to form
b-stranded conformation (Figure 1d). Strikingly, by use of CD and
NMR spectroscopy, we provide here the first residue-specific
evidence that VAPC is in fact highly unstructured in solution,
lacking of any stable secondary structure and tight tertiary
packing. More surprisingly, NMR parameters such as conforma-
tional shifts and NOE connectivity patterns reveal that unlike the
MSP domain also characterized by NMR spectroscopy [37], in
VAPC, no b-strand conformation is populated. Instead, loop or
helical-like conformations are identified to be weakly populated
over several regions of the VAPC sequence. This observation is
consistent with the notion that the formation of b-sheet
conformation requires the stabilization of complex long-range
interaction networks, and thus is highly context-dependent
[53,54]. Indeed, by NMR characterizations from our and other
groups, the classic SH3 b-barrel fold adopted by .4,000
sequences has been previously unraveled to transform into helical
conformations at certain solution conditions [55,56] or triggered
by mutations [55,57]. In particular, we also demonstrated that one
ALS-causing mutation (P56S) is sufficient to eliminate the b-barrel
fold of the human VAPB-MSP domain, and to trigger the
conversion into the highly-unstructured state only with weakly
populated conformation [37]. Therefore, in VAPC, replacement
of the remaining sequence of the 125-residue VAPB-MSP domain
by 29 residues unique to VAPC is anticipated to disrupt the long-
range interaction network critical for specifying or/and stabilizing
the MSP fold. Consequently, VAPC would lose the ability to form
b-stranded conformation, only with weakly-populated loop or
helical conformations which are mostly stabilized by local
interactions [53–57].
On the other hand, we have demonstrated that despite being
highly disordered, VAPC is indeed active in binding to NS5B, with
an average dissociation constant of ,20 mM by use of NMR
spectroscopy. This renders VAPC as an intrinsically unstructured
protein. Interestingly, since the first 70 residues assume a well-
folded b-stranded conformation in the context of the MSP
Figure 7. Binding of VAPC-14 with NS5B. (a) Far-UV CD spectrum of VAPC-14. (b) Superimposition of 1H-15N NMR HSQC spectra of VAPC-14 in
the absence of (black) and in the presence of unlabeled NS5B at molar ratios of 0.5 (pink), 1:1 (blue), and 1:2.5 (green) (VAPC-14:NS5B). The sequential
assignments of VAPC-14 are labeled. (c) Residue-specific changes of integrated 1H and 15N chemical shifts of VAPC-14 in the presence of unlabeled
NS5B at molar ratios of 1:0.5 (blue); 1:1 (green) and 1:2.5 (red) (VAPC-14:NS5B). (d) Experimental (dots) and fitted (lines) values are shown for VAPC-14
residues with significant changes of the integrated 1H and 15N chemical shifts.
doi:10.1371/journal.pone.0040341.g007
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domain, VAPC slightly differs from the classic ‘‘intrinsically-
unstructured proteins’’ that usually harbor relatively degenerative
sequences with a high percentage of polar and charged residues
[58–64]. Also very surprisingly, even upon binding to NS5B,
VAPC and its fragments still lack any tight tertiary packing
required to manifest large spectral dispersions of the HSQC
spectrum. In fact, we previously found a similar phenomenon with
a transcriptional activator ApLLP for long-term memory forma-
tion, which is not only highly disordered in the free state, but
intriguingly remains largely unstructured even upon forming a
complex with DNA [65]. Similarly, no high-quality ITC profile
could be obtained for the ApLLP-DNA interaction. Currently, this
phenomenon is starting to be recognized to actually exist in a large
variety of protein-protein and protein-DNA complexes involved in
intrinsically unstructured proteins, and thus being designated as
the ‘‘fuzzy complex’’ [66,67]. The fuzzy or dynamic property of
the VAPC-NS5B complex is most likely to result from its discrete
multi-binding site scenario for which the binding affinity of each
separate site is relatively low [68], and also many residues are not
significantly engaged in binding to NS5B and consequently remain
flexible (Figure 5b).
NMR characterization allows the identification of VAPC
residues critical for binding to NS5B. Interestingly, it appears
that three discrete VAPC regions are involved in binding with
NS5B. The first centered at Ile62 and the third centered at Glu95
are very short, while the second region is much longer, spanning
Arg73-Ala82 (Figure 6b). Interestingly, only the first is located
within the identical sequence of VAPC and VAPB, while the
second and third are both within the VAPC unique sequence. The
key role of the second region was further confirmed by
characterizing a VAPC-43 mutant which dramatically lost binding
ability to NS5B. Nevertheless, the first and third regions also
contribute to interaction with NS5B to a certain degree, since
VAPC-14 (with the first and third regions deleted) exhibited a ,3-
fold loss of binding affinity (Table 1). In conclusion, VAPC-14 may
be useful for exploring the biological functions of VAPC in vivo,
and also represents a promising starting point to develop potent
peptide inhibitors for interfering with the VAPC-NS5B interface
in the treatment of HCV infection by use of NMR-guided
approaches [68–70].
Materials and Methods
Cloning, Expression and Purification
The VAPC gene was constructed by first amplifying the DNA
fragment encoding the N-terminal 70 residues identical to VAPB
from our previous MSP construct [37], followed by linking to the
de novo synthesized DNA fragment for the 29 residues unique to
VAPC [48]. The genes for truncated and mutated VAPC
(including VAPC-43 and its mutant VAPC-14) were generated
by PCR using different pairs of primers. The full-length VAPC
was cloned into pET32a expression vector, while VAPC-43 and its
mutant VAPC-14 were cloned in pGEX-4T-1. The NS5B gene
was PCR-amplified from the pXJ40flag-NS5B plasmid, which
contains NS5B of HCV genotype 1b [71], and then cloned into
pET32a.
All the expression vectors were transformed into Escherichia coli
BL21 (DE3) Star cells (Invitrogen). For expression of recombinant
proteins, cells were grown in Luria-Bertani (LB) medium in the
presence of ampicillin (100 mg/ml) at 37uC to reach an
absorbance of 0.6 at 600 nm, and subsequently induced with
optimized IPTG concentrations. Harvested cells were resuspended
and lysed by sonication in lysis buffer (50 mM Tris, 500 mM
NaCl, 10% glycerol, 20 mM imidazole, 10 mM 2-mercaptoeth-
anol, pH 7.5) containing protease inhibitor cocktail (Roche). His-
tagged proteins were purified by Ni2+-affinity chromatography
(Qiagen), while GST-fused proteins were purified by affinity
chromatography with glutathione-Sepharose 4B beads (Pharmacia
Biotech) under native conditions. The recombinant proteins were
released from the fused tags by in-gel thrombin cleavage, and
further purified either by FPLC on a Superdex 200 column for
NS5B (Pharmacia Biotech), or by HPLC on RP (reverse phase) C8
and C18 columns (Vydac) for VAPC, VAPC-43 and its mutant
VAPC-14, respectively. The purity of all protein samples was
checked by SDS-PAGE, and their molecular masses were verified
by a Voyager STR matrix-assisted laser desorption ionization
time-of-flight-mass spectrometer (Applied Biosystems).
The production of the isotope-labeled VAPC and its fragment
or mutant proteins for NMR studies followed a similar procedure
except that the bacteria were grown in M9 medium with the
addition of (15NH4)2SO4 for
15N labeling and (15NH4)2SO4/[
13C]-
glucose for 15N2/13C double labeling [37,38,48,49]. The
identities of VAPC and its fragment or mutant proteins were
further confirmed by NMR assignments. The concentration of
protein samples was determined by the spectroscopic method in
the presence of denaturant [37,38,48,49,72].
Circular Dichroism (CD) and NMR Experiments
All CD experiments were carried out in a Jasco J-810
spectropolarimeter (Jasco Corporation) at 25uC as previously
described [37,38,48,49]. The protein concentration was 20 mM in
2 mM phosphate buffer (pH 6.5) for all far-UV CD experiments.
NMR samples were prepared in 10 mM phosphate buffer in the
presence of 10 mM DTT (pH 6.5). All NMR data were collected
at 25uC on an 800-MHz Bruker Avance spectrometer equipped
with a shielded cryoprobe as described before [37,38,48,49]. For
HSQC characterization, samples were prepared at a protein
concentration of 100 mM. For sequential assignments of VAPC,
triple-resonance NMR experiments including HNCACB and
CBCA(CO)NH were acquired on a double-labeled sample at a
protein concentration of ,300 mM. For sequential assignments of
Table 1. Residue-specific dissociation constants (Kd) for the
binding of NS5B to VAPC-43 and VAPC-14.
Residues VAPC43 VAPC14














Note: underlined Kd values have large errors, and thus were not included for
calculating the average Kd values.
doi:10.1371/journal.pone.0040341.t001
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VAPC-43, three-dimensional heteronuclear NMR experiments
including HSQC-TOCSY and HSQC-NOESY were acquired on
a 15N-labeled sample at a protein concentration of ,500 mM.
NMR data were processed with NMRpipe [73] and analyzed with
NMRview [74].
NMR Characterization of Binding Interactions
For NMR HSQC characterization of the binding interactions of
NS5B to VAPC fragments or mutant, two-dimensional 1H-15N
HSQC spectra of the 15N-labeled VAPC proteins were acquired at
a protein concentration of 100 mM in the absence or presence of
the unlabeled NS5B at different molar ratios. By superimposing
the HSQC spectra at different molar ratios, the shifted or
disappeared HSQC peaks could be identified, and further assigned
to the corresponding residues as previously described
[37,38,48,49]. The degree of perturbation was reflected by an
integrated chemical shift difference (CSD) calculated by the
formula ((D1H)2+ (D15N)2/5)1/2 [48]. The CSD tracings were
fitted by using the one binding site model [49] to obtain residue-
specific dissociation constants (Kd) as summarized in Table 1.
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